Evaluation of nikkomycin Z with frequent oral administration in an experimental model of central nervous system coccidioidomycosis
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.01356-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Nathan P Wiederhold und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Fungus Testing Laboratory, University of Texas Health Science Center at San Antonio, San Antonio, Te…. Hauptthemen laut MEDLINE: Aminoglycosides, Antifungal Agents, Disease Models, Animal, Coccidioidomycosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CLC NIH HHS, ORFDO NIH HHS, NIAID/NIH.
Abstract (Originalsprache)
We evaluated the in vivo activity of nikkomycin Z against central nervous system coccidioidomycosis. Mice were inoculated intracranially with arthroconidia of Coccidoides immitis , and treatment with nikkomycin Z (50, 100, or 300 mg/kg orally TID) or fluconazole (25 mg/kg orally BID) began 2 days later. Each dose of nikkomycin Z and fluconazole significantly improved survival and reduced brain fungal burden compared with vehicle control. Further studies of nikkomycin Z against coccidioidomycosis are warranted. IMPORTANCE Coccidioides species are endemic fungi that are capable of causing disease in patients with various comorbidities, as well as in otherwise healthy individuals. Treatment options for coccidioidomycosis are suboptimal, as azole antifungals may be limited by drug interactions and adverse effects due to interactions with enzymes found in humans and other mammals. Nikkomycin Z is an investigational agent that works against a target specific to the fungal cell wall (chitin), which is not present in the cells of humans or other mammals. In this study, we show that frequent oral administration of nikkomycin Z is effective in an experimental model of central nervous system coccidioidomycosis. Further studies of nikkomycin Z against coccidioidomycosis may be warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Fungus Testing Laboratory, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
- Department of Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
- Valley Fever Solutions, Inc., Tucson, Arizona, USA.
ORCID-Profile: Nathan P Wiederhold
Förderung
- CLC NIH HHS
- ORFDO NIH HHS
- NIAID/NIH
Zitieren
APA
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Larwood, D. J., & Patterson, T. F. (2024). Evaluation of nikkomycin Z with frequent oral administration in an experimental model of central nervous system coccidioidomycosis. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01356-24
Vancouver
Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Larwood DJ, Patterson TF. Evaluation of nikkomycin Z with frequent oral administration in an experimental model of central nervous system coccidioidomycosis. Microbiology Spectrum. 2024. doi:10.1128/spectrum.01356-24
BibTeX
@article{Wiederhold2024,
author = {Wiederhold, Nathan P and Najvar, Laura K and Jaramillo, Rosie and Olivo, Marcos and Larwood, David J and Patterson, Thomas F},
title = {Evaluation of nikkomycin Z with frequent oral administration in an experimental model of central nervous system coccidioidomycosis},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.01356-24}
}
EUVIMED